Global capabilities
Delivering value beyond the test result
At Mayo Clinic Laboratories, laboratory medicine is about more than a test result — it’s about everything that contributes to providing answers for your patients. We develop individualized support solutions for each client that extend through all aspects of the relationship to ensure the delivery of answers, not just results.
Specialized testing areas include:
Global logistics and shipping
We develop unique relationships with each client to individualize logistics support, which is coordinated by a local team who ensures a seamless process before the first patient specimen is sent. Our specialists collaborate with packaging suppliers to create unique solutions that extend the stability of specimens traveling around the world.
These experts ensure specimens are handled carefully and efficiently through close connections to shipping carriers. The air carriers we work with are experienced with processing clinical specimens.
Optimized, expeditious processing
We recognize many medical conditions have a window of opportunity for the best possible outcomes. Our tests and processes are optimized to better serve patients and deliver results with outcomes in mind. We do not triage specimens across a network of labs or use a batch-testing business model. Result turnaround times are expedited by:
- Running tests continuously – your samples are processed alongside those from Mayo Clinic.
- A testing approach that incorporates comprehensive panels and algorithms when appropriate.
- Utilization of Lean and Six Sigma processes.
Reliable connectivity
We offer technology solutions to help our clients connect to us, including a secure online portal with interfacing capabilities that allows you to easily order tests and receive results. Our solutions include:
- Client-friendly test ordering through MayoLINK, which is available in eight languages.
- Expansive website with links to our open- access test catalog, which is updated daily and features comprehensive clinical information, including specimen requirements; clinical and interpretative information; performance; sample test reports; setup files; and pricing.
- 30 country-specific toll-free numbers.
News and updates
The latest
Accurate coagulation testing starts with proper specimen preparation. Even small pre-analytic errors, such as underfilled tubes, hemolysis, or improper centrifugation, can compromise results and patient care.
This week's research roundup features: Gastrointestinal stromal tumors mimicking gynecologic disease: clinicopathological analysis of 20 cases.
This page includes updates posted to mayocliniclabs.com during the month of July.
In this month's "Hot Topic," Rajiv Pruthi, M.B.B.S., discusses heparin induced thrombocytopenia (HIT), approach diagnosis, and the role of the functional serotonin release assay (SRA).
Topic highlights include: Mayo Clinic in Rochester again ranked country's top hospital: U.S. news and world report, WHO declares monkeypox a global health emergency as infections soar, Depression is likely not caused by a chemical imbalance in the brain, study says.
William Morice II, M.D., Ph.D., president of Mayo Clinic Laboratories, shares his concerns about the VALID Act, which if passed would give the FDA oversight of laboratory-developed tests. VALID could hamper labs’ test development activity, increase costs for labs, and disproportionately affect smaller labs or those with fewer resources. It could also lead to more test development partnerships and lab collaboration.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with podcast host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the World Health Organization’s declaration of monkeypox as a global public health emergency, how Mayo Clinic Laboratories quickly implemented testing, and the public-private partnership to manage the response.
Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for managing clinical care.
This week's research roundup features: Motor-neuron-disease-like phenotype associated with IgLON5 disease.
Results of a new study by researchers at Mayo Clinic and Washington State University show that hydrogen peroxide-producing e-bandages may be an effective alternative to antibiotics for managing infected wounds.
Topic highlights include: Mayo Clinic platform leader Dr. John Halamka turning 'healthcare data into wisdom', Loss of smell, taste no longer predominant COVID symptoms as virus continues to mutate, UK study: Don’t ruin your cookout by serving E. coli.
In this episode, Dr. Pritt and Dr. Morice discuss the science behind the increasing COVID-19 infections, why individuals can get reinfected with different variants, and the effectiveness of the at-home antigen tests.
Working with Mayo Clinic BioPharma Diagnostics clients, Grant Elmquist is engaged in a wide range of activities that span research and science technology, as well as a host of disease states, all with the end goal of enhancing patient care.